Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications
Authors:
- 10 September 2013
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 16 (11) , 1275-1289
Abstract
Objective: To compare treatment persistence in attention-deficit/hyperactivity disorder (ADHD) of patients initiated on lisdexamfetamine (LDX) vs other ADHD medications. Methods: A large US administrative claims database was used to select ADHD patients who initiated an ADHD medication (index treatment) during/after 2007. Patients were classified, based on age and previous treatment status, as treatment-naïve or previously treated children and adolescents (6–17 years) and treatment-naïve or previously treated adults (18 years and older). Furthermore, patients were classified into seven mutually exclusive treatment groups, based on their index treatment: LDX, atomoxetine (ATX), osmotic-release methylphenidate hydrochloride long-acting (OROS MPH), other methylphenidate/dexmethylphenidate short-acting (MPH SA) and long-acting (MPH LA), and amphetamine/dextroamphetamine short acting (AMPH SA) and long-acting (AMPH LA). Treatment persistence, analyzed through discontinuation (interruption of the index treatment for ≥30 consecutive days), was compared between treatment groups using multivariate Cox proportional hazards. Patients were followed until first treatment discontinuation or up to 12 months after the initiation of the index treatment, whichever occurred first. Results: Among children and adolescents, LDX patients had a significantly lower discontinuation rate compared to other treatment groups (range hazard ratios [HRs]; 1.04–2.26; all p < 0.05), except when compared to treatment-naïve patients on ATX and OROS MPH, where no statistically significant differences were found and where LDX had a higher risk of discontinuation, respectively. Among adults, LDX patients had a significantly lower discontinuation rate compared to patients in other treatment groups (range HR; 1.14–1.86; all p < 0.05), except for the comparison with AMPH LA patients, where differences were not statistically significant. Limitations: This study did not control for ADHD severity. Conclusion: LDX-treated patients were associated with higher persistence compared to patients initiated on other ADHD medications, except for the comparisons with OROS MPH and ATX treated patients in treatment-naïve children and adolescents and AMPH LA-treated patients in adults.Keywords
This publication has 21 references indexed in Scilit:
- Driving performance in adults with ADHD: Results from a randomized, waiting list controlled trial with atomoxetineEuropean Psychiatry, 2013
- A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatmentBMC Medicine, 2012
- A lifetime of attention-deficit/hyperactivity disorder: diagnostic challenges, treatment and neurobiological mechanismsExpert Review of Neurotherapeutics, 2011
- ADHD medication use, adherence, persistence and cost among Texas Medicaid childrenCurrent Medical Research and Opinion, 2011
- Developmental processes in peer problems of children with attention-deficit/hyperactivity disorder in The Multimodal Treatment Study of Children With ADHD: Developmental cascades and vicious cyclesDevelopment and Psychopathology, 2010
- The quality of life of children with attention deficit/hyperactivity disorder: a systematic reviewEuropean Child & Adolescent Psychiatry, 2009
- Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adultsThe British Journal of Psychiatry, 2009
- Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorderEuropean Child & Adolescent Psychiatry, 2006
- Impact of Age at Onset and Duration of Illness on the Expression of Comorbidities in Obsessive-Compulsive DisorderThe Journal of Clinical Psychiatry, 2004
- A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity DisorderArchives of General Psychiatry, 1999